Loading…
Biomerica, Inc. is projected to rise to $1.73 by 2027, a +13% move from its current price of $1.53. BMRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.50 | $1.53 | $1.57 | +0.03% |
| Aug 6 | $1.48 | $1.53 | $1.58 | +0.06% |
| Aug 7 | $1.47 | $1.53 | $1.59 | +0.09% |
| Aug 8 | $1.46 | $1.53 | $1.60 | +0.12% |
| Aug 9 | $1.46 | $1.53 | $1.61 | +0.14% |
| Aug 10 | $1.45 | $1.53 | $1.62 | +0.17% |
| Aug 11 | $1.44 | $1.53 | $1.63 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.44 | $1.53 | $1.63 | +0.20% |
| Week 2 | $1.41 | $1.54 | $1.67 | +0.41% |
| Week 3 | $1.39 | $1.54 | $1.71 | +0.61% |
| Week 4 | $1.37 | $1.54 | $1.74 | +0.81% |
| Week 5 | $1.35 | $1.55 | $1.77 | +1.02% |
| Week 6 | $1.34 | $1.55 | $1.80 | +1.22% |
| Week 7 | $1.32 | $1.55 | $1.82 | +1.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. Its operations span creating and commercializing diagnostic test kits and related products used to analyze blood, urine, nasal or fecal specimens, with applications in diagnosing diseases, food intolerances, and other medical complications, as well as measuring specific substances in the body in extremely small concentrations.
InFoods IBS, which uses a simple blood sample to identify patient-specific foods that may alleviate irritable bowel syndrome symptoms, and hp+detect, a Helicobacter pylori diagnostic test, are among its development efforts; the company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the InFoods platform in Canada. Biomerica was incorporated in 1971 and is headquartered in Irvine, California.
Biomerica, Inc. (BMRA) is currently priced at $1.49 per share, with a market capitalization of $4.6M and a rank of 5304. The stock trades with a neutral technical tenor, and the latest price sits near a defined support level.
The near-term price structure shows the stock trading below key moving averages, with notable volatility in the setup. On the horizon, the forecast lay out provides a trajectory from 2026 through 2050 with rising average prices and growing bullish sentiment in later years.
A major floor 18.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 20.9% above — a clean break opens room to run.
A major ceiling 62.7% above — clearing it would confirm fresh momentum.
Key BMRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.58 | Sell | $1.56 | Sell |
| MA 10 | $1.59 | Sell | $1.59 | Sell |
| MA 20 | $1.63 | Sell | $1.64 | Sell |
| MA 50 | $1.89 | Sell | $1.81 | Sell |
| MA 100 | $2.03 | Sell | $1.99 | Sell |
| MA 200 | $2.25 | Sell | $2.29 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.40 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -217.25 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -10.78 | Sell |
| Bollinger %B (20,2) | -0.14 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.75 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 29.56 | Buy |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.56 | Sell |
| ADX (14) | 33.32 | Sell |
| ATR (14) | 0.04 | Info |
In the near term, sentiment remains NEUTRAL with the RSI14 at 30, indicating a position near the lower end of the range. The stock is trading below its SMA50 of $1.89 and its SMA200 of $2.25, which suggests a weaker near-term trend relative to the moving averages. The current price of $1.49 sits at the defined support level of $1.49, while resistance is at $1.85.
The 30-day price range spans from $1.28 to $1.73, highlighting a relatively tight trading band ahead of potential moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.49 | $1.53 | $1.95 | 0% | Neutral | |
| $1.40 | $1.73 | $2.25 | +13% | Neutral | |
| $1.38 | $1.75 | $2.35 | +14% | Neutral | |
| $1.35 | $1.74 | $2.39 | +14% | Neutral | |
| $1.38 | $1.81 | $2.54 | +18% | Neutral | |
| $1.39 | $1.85 | $2.65 | +21% | Bullish | |
| $1.60 | $2.16 | $3.14 | +41% | Bullish | |
| $1.77 | $2.42 | $3.57 | +58% | Bullish | |
| $1.77 | $2.45 | $3.67 | +60% | Bullish | |
| $1.75 | $2.45 | $3.71 | +60% | Bullish | |
| $2.34 | $3.46 | $5.55 | +126% | Bullish | |
| $3.55 | $5.75 | $9.97 | +276% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.49 | $1.53 | $1.83 | +0.00% |
| September 2026 | $1.30 | $1.52 | $1.84 | -0.39% |
| October 2026 | $1.33 | $1.57 | $1.91 | +3.08% |
| November 2026 | $1.35 | $1.61 | $1.97 | +2.47% |
| December 2026 | $1.33 | $1.58 | $1.95 | -1.65% |
Click any year to see its month-by-month BMRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BMRA could reach as high as $1.95, with a base case around $1.53 and support toward $1.49 — roughly 0% from $1.53. A consolidation phase looks the most probable path here.
Expect BMRA to range from $1.40 to $2.25 through 2027. The $1.73 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. Price action looks broadly range-bound.
The BMRA price prediction for 2028 points to an average of $1.75 (low $1.38, high $2.35) — a potential gain of +14% on today's $1.53. A consolidation phase looks the most probable path here.
In 2029, BMRA is projected to trade between $1.35 and $2.39, averaging $1.74 — a potential gain of +14% from today's $1.53. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
Biomerica, Inc.'s 2030 outlook centres on $1.81, within a $1.38 to $2.54 range. That is up +4% on the projected 2029 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, BMRA could reach as high as $2.65, with a base case around $1.85 and support toward $1.39 — roughly +21% from $1.53. Momentum favours further upside here.
Expect BMRA to range from $1.60 to $3.14 through 2032. The $2.16 average target implies a +41% move from current prices. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The BMRA price prediction for 2033 points to an average of $2.42 (low $1.77, high $3.57) — a potential gain of +58% on today's $1.53. Momentum favours further upside here.
In 2034, BMRA is projected to trade between $1.77 and $3.67, averaging $2.45 — a potential gain of +60% from today's $1.53. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Biomerica, Inc.'s 2035 outlook centres on $2.45, within a $1.75 to $3.71 range. That is 0% versus the projected 2034 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2040, BMRA could reach as high as $5.55, with a base case around $3.46 and support toward $2.34 — roughly +126% from $1.53. Buyers look set to stay in control over this stretch.
Expect BMRA to range from $3.55 to $9.97 through 2050. The $5.75 average target implies a +276% move from current prices. That is up +66% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BMRA today (≈ 653.594771 BMRA) could be worth
$3,756.17
+$2,756.17 (+276%) by 2050 · US Dollar
Based on the average projected BMRA price of $5.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMRAwould be worth at today's price.
$1,000 invested in BMRA on Jul 31, 2025 (≈ 308.641974 BMRA) would be worth
$472.22
-$527.78 (-52.8%) today · 0.47× · US Dollar
Based on a BMRA entry price of $3.24 vs. today's $1.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.59 | $962.26 | -3.8% |
| 1 month ago | $1.8 | $850 | -15.0% |
| 3 months ago | $2.19 | $698.63 | -30.1% |
| 6 months ago | $2.41 | $634.85 | -36.5% |
| 1 year ago | $3.24 | $472.22 | -52.8% |
| All time (5.0y) ago | $31.6 | $48.42 | -95.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMRA forecast.
Our base-case forecast reaches $3.10 around 2040.
Implied market cap at $3.10: $9.58M
The multi-year forecast shows a gradual ascent from 2026 through 2030, with 2026 projecting an average price near $1.49 and 2030 an average of $1.76 and a max of $2.48, yielding a 18.4 in ROI terms. From 2031 onward, the outlook turns more bullish, with 2031 averaging $1.81 and max $2.58 (ROI 21.2), and 2032 averaging $2.11 (ROI 41.3), followed by continued gains through 2033–2035. By 2040 the forecast reaches an average of $3.37 with a max of $5.41 (ROI 126.5), and by 2050 it projects an average of $5.60 with a max of $9.72 (ROI 276).
The sentiment flips to BULLISH in 2031 and remains so into 2040 and 2050. These figures are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
2030 avg $1.76; min $1.35; max $2.48; ROI 18.4; sentiment NEUTRAL.
Near-term forecasts show flat to modest gains (2026 avg $1.49; 2027 avg $1.69; 2028 avg $1.71; 2029 avg $1.69) with a shift to bullish sentiment from 2031 onward, culminating in higher averages and ROIs by 2040 and 2050 (e.g., 2040 avg $3.37; 2050 avg $5.60; 2050 max $9.72). These are estimates, not guarantees.
No. The forecast shows a 2050 max of $9.72, which does not reach $10.
2031 max $2.58.
Biomerica, Inc. Community Discussion
0Share your Biomerica, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.